Horizon Therapeutics (Nasdaq: HZNP) has announced new data on Uplinza (inebilizumab-cdon) were presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with neuromyelitis optica spectrum disorder (NMOSD).
Uplinza is the first and only Food and Drug Administration-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Horizon picked up rights to Uplinza along with its $3.05 acquisition of Viela Bio, which was announced in February this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze